Drug Information

Drug General Information
Drug ID
D0O2XJ
Former ID
DIB013496
Drug Name
NXN-188
Synonyms
Acute migraine therapy, NeurAxon; NXN-188 (oral); NXN-188 (oral), NeurAxon
Drug Type
Small molecular drug
Indication Migraine [ICD9: 346; ICD10:G43] Phase 2 [522692]
Company
Neuraxon
Formula
C27H36N8O5
PubChem Compound ID
123853
Target and Pathway
Target(s) 5-hydroxytryptamine 1B receptor Target Info Modulator
5-hydroxytryptamine 1D receptor Target Info Modulator
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapsehsa04024:cAMP signaling pathway
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway
GPCR downstream signaling
References
Ref 522692ClinicalTrials.gov (NCT00920686) Study of NXN 188 for the Treatment of Migraine With Aura. U.S. National Institutes of Health.